Volume Alert - SNY 47.45 Sanofi-Aventis Sa $SNY Hi
Post# of 65
Posted On: 11/17/2014 2:10:41 PM
Volume Alert - SNY 47.45 Sanofi-Aventis Sa $SNY Hit a high today of 47.54 Closing the day 10:29 at 47.45 +0.77 +1.65% With a day low of 46.83 and a total volume of 1,070,315.
SNY Recent Posts: http://investorshangout.com/Sanofi-SNY-52680/
SNY Sanofi-Aventis Sa Recent Headline News
Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST
SHPG: 205.83 (+3.21), SNY: 47.45 (+0.77), FOLD: 6.92 (+1.23)
CVRs on Lemtrada +135% following approval
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:19AM CST
GCVRZ: 0.92 (+0.41), SNY: 47.45 (+0.77)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 72.47 (-0.38), LLY: 67.31 (-0.02), ABBV: 65.08 (+1.08), GSK: 45.87 (+0.13), SNY: 47.45 (+0.77), NVS: 94.48 (+0.53)
Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 205.83 (+3.21), SNY: 47.45 (+0.77), FOLD: 6.92 (+1.23)
Genzyme's Lemtrada approved by the FDA
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:47PM CST
GCVRZ: 0.92 (+0.41), SNY: 47.45 (+0.77)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 304.54 (-0.89), ISIS: 48.89 (-0.12), AZN: 72.47 (-0.38), SNY: 47.45 (+0.77)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 100.51 (-1.55), AMGN: 159.18 (+1.50), SNY: 47.45 (+0.77), REGN: 400.43 (+5.23)
Healthcare's Top Dividend Paying Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 13, 6:43AM CST
Source: Flickr user TaxRebate.org.uk. Dividends are the foundation to which all great long-term portfolio are built. Receiving a payment equal to 2% or 3% per year might not seem like much, but reinvested into that same growing company over the...
VIVO: 16.14 (-0.05), PETS: 13.60 (-0.01), GSK: 45.87 (+0.13), SNY: 47.45 (+0.77), PDLI: 7.89 (+0.10)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 208.64 (+9.99), ABBV: 65.07 (+1.07), SNY: 47.45 (+0.77), REGN: 400.43 (+5.23)
Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 47.45 (+0.77), REGN: 400.43 (+5.23)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.03 (+0.28), AGN: 208.64 (+9.99), ACT: 247.18 (+3.41), VRX: 135.20 (+0.99), MDT: 69.58 (+0.63), SLXP: 101.21 (-1.11), SNY: 47.45 (+0.77)
PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:20AM CST
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.88 (+0.88), SNY: 47.45 (+0.77), PDLI: 7.89 (+0.10)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.58 (+0.51), AZN: 72.47 (-0.38), AMGN: 159.18 (+1.50), TEVA: 57.55 (+0.48), THRX: 13.22 (-0.01), GSK: 45.87 (+0.13), SNY: 47.45 (+0.77), REGN: 400.43 (+5.23), NVS: 94.48 (+0.53)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.37 (+0.07), SNY: 47.45 (+0.77), REGN: 400.43 (+5.23)
Look for Shares of Sanofi-Aventis to Potentially Pullback after Yesterday's 1.09% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 47.45 (+0.77)
Sanofi-Aventis Set to Possibly Pullback After Yesterday's Rally of 1.09%
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 47.45 (+0.77)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.12 (-0.13), SNY: 47.45 (+0.77), GNW: 9.33 (-0.08), REGN: 400.43 (+5.23)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 43.66 (-0.47), PFE: 30.31 (-0.03), LLY: 67.31 (-0.02), MNKD: 6.18 (+0.02), SNY: 47.45 (+0.77)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 304.54 (-0.89), ALNY: 88.91 (-1.21), ISIS: 48.89 (-0.12), OGXI: 2.20 (+0.02), TEVA: 57.55 (+0.48), RGLS: 16.78 (-0.42), GSK: 45.88 (+0.14), SNY: 47.45 (+0.77)
SNY Recent Posts: http://investorshangout.com/Sanofi-SNY-52680/
SNY Sanofi-Aventis Sa Recent Headline News
Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST
SHPG: 205.83 (+3.21), SNY: 47.45 (+0.77), FOLD: 6.92 (+1.23)
CVRs on Lemtrada +135% following approval
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:19AM CST
GCVRZ: 0.92 (+0.41), SNY: 47.45 (+0.77)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 72.47 (-0.38), LLY: 67.31 (-0.02), ABBV: 65.08 (+1.08), GSK: 45.87 (+0.13), SNY: 47.45 (+0.77), NVS: 94.48 (+0.53)
Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 205.83 (+3.21), SNY: 47.45 (+0.77), FOLD: 6.92 (+1.23)
Genzyme's Lemtrada approved by the FDA
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:47PM CST
GCVRZ: 0.92 (+0.41), SNY: 47.45 (+0.77)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 304.54 (-0.89), ISIS: 48.89 (-0.12), AZN: 72.47 (-0.38), SNY: 47.45 (+0.77)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 100.51 (-1.55), AMGN: 159.18 (+1.50), SNY: 47.45 (+0.77), REGN: 400.43 (+5.23)
Healthcare's Top Dividend Paying Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 13, 6:43AM CST
Source: Flickr user TaxRebate.org.uk. Dividends are the foundation to which all great long-term portfolio are built. Receiving a payment equal to 2% or 3% per year might not seem like much, but reinvested into that same growing company over the...
VIVO: 16.14 (-0.05), PETS: 13.60 (-0.01), GSK: 45.87 (+0.13), SNY: 47.45 (+0.77), PDLI: 7.89 (+0.10)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 208.64 (+9.99), ABBV: 65.07 (+1.07), SNY: 47.45 (+0.77), REGN: 400.43 (+5.23)
Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 47.45 (+0.77), REGN: 400.43 (+5.23)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.03 (+0.28), AGN: 208.64 (+9.99), ACT: 247.18 (+3.41), VRX: 135.20 (+0.99), MDT: 69.58 (+0.63), SLXP: 101.21 (-1.11), SNY: 47.45 (+0.77)
PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:20AM CST
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.88 (+0.88), SNY: 47.45 (+0.77), PDLI: 7.89 (+0.10)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.58 (+0.51), AZN: 72.47 (-0.38), AMGN: 159.18 (+1.50), TEVA: 57.55 (+0.48), THRX: 13.22 (-0.01), GSK: 45.87 (+0.13), SNY: 47.45 (+0.77), REGN: 400.43 (+5.23), NVS: 94.48 (+0.53)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.37 (+0.07), SNY: 47.45 (+0.77), REGN: 400.43 (+5.23)
Look for Shares of Sanofi-Aventis to Potentially Pullback after Yesterday's 1.09% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 47.45 (+0.77)
Sanofi-Aventis Set to Possibly Pullback After Yesterday's Rally of 1.09%
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 47.45 (+0.77)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.12 (-0.13), SNY: 47.45 (+0.77), GNW: 9.33 (-0.08), REGN: 400.43 (+5.23)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 43.66 (-0.47), PFE: 30.31 (-0.03), LLY: 67.31 (-0.02), MNKD: 6.18 (+0.02), SNY: 47.45 (+0.77)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 304.54 (-0.89), ALNY: 88.91 (-1.21), ISIS: 48.89 (-0.12), OGXI: 2.20 (+0.02), TEVA: 57.55 (+0.48), RGLS: 16.78 (-0.42), GSK: 45.88 (+0.14), SNY: 47.45 (+0.77)
(0)
(0)Sanofi (SNY) Stock Research Links
Scroll down for more posts ▼